Compare EW & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EW | BDX |
|---|---|---|
| Founded | 1958 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.9B | 43.0B |
| IPO Year | 1999 | 1998 |
| Metric | EW | BDX |
|---|---|---|
| Price | $88.97 | $176.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 13 |
| Target Price | $96.37 | ★ $186.00 |
| AVG Volume (30 Days) | ★ 5.0M | 1.7M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.89% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.07 | 0.25 |
| Revenue | $6,067,600,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $13.39 | N/A |
| Revenue Next Year | $9.81 | $3.02 |
| P/E Ratio | ★ $83.48 | $708.28 |
| Revenue Growth | ★ 11.55 | 8.24 |
| 52 Week Low | $72.30 | $140.11 |
| 52 Week High | $96.29 | $213.08 |
| Indicator | EW | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 72.34 |
| Support Level | $81.88 | $163.44 |
| Resistance Level | $96.29 | $196.05 |
| Average True Range (ATR) | 2.26 | 3.72 |
| MACD | 0.47 | 1.47 |
| Stochastic Oscillator | 78.41 | 96.76 |
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.